CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages

The TGFβ receptor inhibitor galunisertib showed promising efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) in the phase 2 H9H-MC-JBAJ study. Identifying biomarkers for this treatment remains essential. Baseline plasma levels of chemokine CCL3 were integrated with clinical outcomes i...

Full description

Saved in:

Bibliographic Details
Published in:	NPJ precision oncology Vol. 8; no. 1; pp. 246 - 15
Main Authors:	Pietrobono, Silvia, Bertolini, Monica, De Vita, Veronica, Sabbadini, Fabio, Fazzini, Federica, Frusteri, Cristina, Scarlato, Enza, Mangiameli, Domenico, Quinzii, Alberto, Casalino, Simona, Zecchetto, Camilla, Merz, Valeria, Melisi, Davide
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 30-10-2024 Nature Publishing Group Nature Portfolio
Subjects:	631/67/1059/602 692/4028/67/1504/1713 692/53/2423 Biomarkers Cancer Research Cancer therapies Chemokines Gene Therapy Human Genetics Internal Medicine Medical prognosis Medicine Medicine & Public Health Metastasis Oncology Pancreatic cancer Signal transduction Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!